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Mutations in the RNA Component of RNase MRP
Cause a Pleiotropic Human Disease,
Cartilage-Hair Hypoplasia
hypoplasia (CHH) [MIM #250250] (McKusick et al., 1965).
The most prominent characteristic of this recessively
inherited disorder is disproportionate short stature with
adult heights ranging from 104 to 149 cm. Other common
features include hypoplastic hair, ligamentous laxity, de-
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2Department of Medical Genetics disposition to lymphoma and other cancers. The varia-
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00290-Helsinki within sibships (McKusick et al., 1965; Ma¨kitie, 1992;
Finland Ma¨kitie and Kaitila, 1993). CHH was first described in
3Department of Biochemistry the Old Order Amish where it is a common cause of
University of Nijmegen short-limbed short stature (McKusick et al., 1965; McKu-
Nijmegen sick, 2000). The incidence among the Amish was calcu-
The Netherlands lated as 1 in 1340 implicating a carrier frequency as
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The Ohio State University population, the Finns, displays a similar gene enrich-
Columbus, Ohio 43210 ment with a calculated carrier frequency of 1:76 (Ma¨kitie,
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for most or all CHH (locus homogeneity) (Sulisalo et al.,
Finland
1994a, 1995). The critical region has been reduced to less
than 1 Mb of DNA by linkage and linkage disequilibrium
analysis (Sulisalo et al., 1994b) and physical mapping (Vak-
kilainen et al., 1999). However, in spite of intensive studySummary
of candidate genes in the critical region (Ben-Yosef and
Francomano, 1999; unpublished data by the presentThe recessively inherited developmental disorder, car-
authors) the gene has been elusive (McKusick, 2000).tilage-hair hypoplasia (CHH) is highly pleiotropic with
Here we describe mutations in the RMRP gene caus-manifestations including short stature, defective cellu-
ing CHH. This study describes disease-causing muta-lar immunity, and predisposition to several cancers.
tions in a nuclear gene encoding a structural RNA mole-The endoribonuclease RNase MRP consists of an RNA
cule. The untranslated RMRP gene is transcribed bymolecule bound to several proteins. It has at least two
RNA polymerase III, encodes the RNA component of afunctions, namely, cleavage of RNA in mitochondrial
ribonucleoprotein endoribonuclease (Topper and Clay-DNA synthesis and nucleolar cleaving of pre-rRNA.
ton, 1990), and is located in the CHH critical regionWe describe numerous mutations in the untranslated
(Hsieh et al., 1990 and results shown here). NormallyRMRP gene that cosegragate with the CHH pheno-
the RNase MRP complex is involved in multiple cellulartype. Insertion mutations immediately upstream of the
and mitochondrial functions. In the nucleolus this en-coding sequence silence transcription while muta-
donuclease partakes in the processing of pre-rRNAtions in the transcribed region do not. The association
whereas in the mitochondrion it cleaves the RNA primersof protein subunits with RNA appears unaltered. We
responsible for DNA replication (Chang and Clayton,conclude that mutations in RMRP cause CHH by dis-
1989; Clayton, 1994; reviewed by van Eenennaam etrupting a function of RNase MRP RNA that affects
al., 2000). As we did not find any disturbances in themultiple organ systems.
association of specific proteins with RNase MRP RNA
from CHH patients, the disease-causing functional im-Introduction
pairment of the RMRP gene product remains to be char-
acterized. The existence of one or more elusive addi-Pleiotropy, that is, multiple phenotypic manifestations
of a single genetic defect, is a hallmark of McKusick- tional substrates for this endonuclease has been
type metaphyseal chondrodysplasia or cartilage-hair postulated (Tollervey and Kiss, 1997; Cai et al., 1999).
Our findings provide a first step toward an improved
understanding of these processes leading to the pleio-7 To whom correspondence should be addressed (e-mail: ilkka.kaitila@
hus.fi [I. K.], delachapelle-1@medctr.osu.edu [A. d. l. C.]). tropic phenotypic manifestations of CHH.
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Table 1. The New Polymorphic Markers Used in Genetic Mapping. The Order Is from the Telomere to the Centromere
Type of PCR Product
Name Location Polymorphism PCR Primer Sequences (59–39) Size (bp) SSCP Conditions
16P1 Centromeric to AB002373 dup TGCATGCA AAGGATCCTCGCAGCTTTC 182/190 6% Sequagel
GCACCCTGGTCAATGTTTTC
AB12GS AB002373 A/G AGTGGGCCCATATGAAACAC 118 0.73MDE
CCCCTTTGAGTGGTTGCTTAC 4 W 15 hr
Del13 CD72 13 nt deletion GAGGCATGGGGAGTCCAG 103/90 2% SeaKem
GTGGAGGAACTTTCATCCCAG
SIT45S SIT intron 3 T/C GGCTGTGACGCTGCTATTTC 223 0.53MDE
AATGCAGGTTCCCATACAGC 3 W 17 hr
TP2A TPM2 exon 2A G/A CGCTTCTCTCCCCTACAATAG 270 0.73MDE
GACAGAGGGGACTTGGTCAG 5 W 18 hr
TA13S nt 3806 in TLN cDNA C/T CTGTGTCAGCTGCCTACCTG 143 13MDE
AGAGGCCTGGCATTCTTTG 6 W 18 hr
D4S KIAA0582 G/A CATCCTCCTCCAAGAATGGAC 187 0.83MDE
AAACCTCAGCCCTGGCAC 6 W 18 hr
D6S KIAA0582 G/A AATCAGGATCCATTACACCCTC 137 0.73MDE
CAGCTTCTCCCTCCCAATC 4 W 17 hr
CA1 Between 37D7T7 and AC repeat TTCCTTCTGTGTTGGGTGTG z140 6% Sequagel
Z38966 TTCCTATTGAGCCCGATTTG
XL6S Telomeric to EST-C G/A AAGGCTGAGTCTGGGTGATTC 152 0.83MDE
AAGGCAAACAGGGGATTTTC 5 W 17 hr
XL2S Telomeric to EST-C G/A AGACTGAGGTCAGAGGGGGAAG 145 0.83MDE
CGCAAGGCTGGTTCTCTGAG 5 W 17 hr
XL1S Telomeric to EST-C T/C CAAAAGCCCGTGTTGTTCATC 166 0.83MDE
GGTGGAGACAGAGGAGCTGTC 5 W 18 hr
CCS EST-C G/A CATTCGGCACATGAGATACG 145 13MDE
CAGGACTGTGACGTGGAGAG 6 W 17 hr
TG2S T64224 C/T CAGAACCAGCATCATAG 187 13MDE
GGATCCTTGTTATTGGGACAG 5 W 17 hr
Results Genomic and Transcript Map of the CHH Region
The CHH critical region as defined above was contained
in three overlapping BAC clones, 468J10, 199G9, andGenetic Map of the CHH Region
To refine the genetic map of the CHH region in chromo- 497J14 as determined previously (Figure 2 in Vakkilainen
et al., 1999). The region was known to contain severalsome 9p13 beyond our previous map (Vakkilainen et al.,
1999), we developed new polymorphic markers (Table genes and transcripts; however, in an effort to study all
genes, we shotgun-sequenced the three BAC clones and1). Haplotypes were constructed of 116 affected chro-
mosomes from 16 multiplex and 42 uniplex Finnish CHH assembled the middle part of the sequence into three
contigs, 71.6 kb, 187.6 kb, and 122.7 kb in length (acces-families using 23 polymorphic markers. Among the 116
haplotypes, 96 (83%) shared alleles with the presump- sion nos. AF334828 to AF334830). The 145 kb CHH criti-
cal region was fully covered by the largest contig andtive ancestral haplotype, suggestive of a prevalent
shared founder mutation. A graphic representation of contained at least 11 genes as shown in Figure 1B.
those 78 haplotypes in which all alleles could be un-
equivocally assigned to the 23 markers is shown in Fig- Mutational Analysis in CHH Patients
Using available bioinformatics tools and existing data-ure 1A. The “ancestral” haplotype shown uppermost
was observed in 18 chromosomes, whereas all other bases, we mapped and assembled 11 genes in the critical
region that we had sequenced (Figure 1B). We analyzedchromosomes showed a reduction in the length of the
shared haplotype as evidence of historical recombina- all 11 genes by a combination of reverse transcriptase
PCR cDNA sequencing, single-strand conformationaltions. These historical recombinations allowed us to ten-
tatively narrow the critical CHH region to the interval polymorphism (SSCP), and direct genomic PCR se-
quencing in a panel of 7 CHH patients and one noncarrierbetween the TESK1 A/G and D4S markers. This region
was later shown to represent 145 kilobases of DNA. control. No potentially disease-causing mutations were
found in the coding regions of TESK1, CD72, SIT,The degree of linkage disequilibrium between markers
and the disease phenotype can give a hint about the AK001187, MN/CA9, TPM2, TLN, LZIP, AAF53384 ho-
molog, and KIAA0258 genes (data not shown). However,precise location of the sought gene (Ha¨stbacka et al.,
1992) and has proven a powerful tool in the positional the finding of an insertion in the RMRP gene in one CHH
patient focused our attention on RMRP.cloning of numerous genes in the Finnish population (de
la Chapelle and Wright, 1998). The higher the Pexcess
value, the stronger is the linkage disequilibrium and the Mutations in the RMRP Gene
The primary transcript of RMRP (accession no. M29916)closer is the marker to the disease gene (Lehesjoki et
al., 1993). Within the above critical region, Pexcess varied comprises 267 nucleotides and is present in the genome
as a single copy (Chang and Clayton, 1989). RMRP isbetween 0.70 and 0.92 being highest at the adjacent
markers TP2A and TA13S (Figure 1A). transcribed by RNA polymerase III, which is active within
RNase MRP RNA Mutations in Cartilage-Hair Hypoplasia
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Figure 1. Genetic, Physical, and Transcript Map of the CHH Region
(A) Haplotypes of 78 affected chromosomes from Finnish CHH patients are shown. Alleles of the polymorphic markers are arbitrarily numbered.
The uppermost haplotype encountered in 18 chromosomes is considered “ancestral.” Portions of this haplotype that are shared on the
remaining 60 chromosomes are shown in blue. The region shared by all haplotypes extends between markers TESK1 A/G and D4S and is
depicted as the “CHH region.” The telomere is to the left. On top are shown the Pexcess values depicting the degree of linkage disequilibrium
between each marker and the disease phenotype. A peak at markers TP2A and TA13S is seen. An arrow indicates the location of the RMRP
gene.
(B) Shown here is the middle region of the genetic map depicted in (A). Above the line are the 9 polymorphic markers; below the line are the
transcripts. Among the genes in the CHH critical region the ones that were mapped there before the genomic sequence was obtained are
marked in yellow, whereas the ones marked in blue were localized there based on the sequence we generated. RMRP is depicted in red. In
addition to these genes, exon prediction and homologies to human and mouse coding sequences suggested one novel gene immediately
centromeric to AK001187 (MG homolog). A promoter region near the 39 end of TLN and several non-TLN ESTs were found to overlap the 39
end of TLN. These findings may suggest an unknown gene overlapping TLN (TU region). After repeats were masked, exons of the putative
genes were searched using FGENES and GRAIL-1.3 programs. Four exons were predicted for the MG homolog whereas three exons were
predicted for the TU region. Using reverse transcription PCR, we determined that AK001187 and MG homolog belong to the same gene.
the nucleoplasm (Paule and White, 2000). The RMRP scription of RMRP. The second category consists of
single nucleotide substitutions and other changes in-promoter is a type III promoter lacking intragenic pro-
moter elements (Murphy et al., 1987; Paule and White, volving at most two nucleotides. These reside in highly
conserved residues of the transcribed sequence. Table2000). A TATA box is located between 233 and 225, and
additional type III promoter elements are found between 2 summarizes the mutations found in those CHH pa-
tients and families in which a mutation of both alleles267 and 257 (PSE element), 2215 and 2208 (octamer
element), and between 2231 and 2225 (SP1 binding has been identified so far. Figure 2 summarizes the loca-
tion of these mutations.site) (Yuan and Reddy, 1991). We PCR amplified the
entire z1 kb RMRP region in four overlapping fragments, Of note is that while the insertion mutations are of
somewhat different length and location, they all resultand searched for sequence variants by direct se-
quencing. in a lengthening of the important distance between the
TATA box and the transcription initiation site. RegardingThe mutations are of two distinct types. The first cate-
gory consists of insertions or duplications between 6 the 4 different mutations in the transcribed sequence,
we note that all are located at sites that are conservedand 30 nucleotides long residing in the region between
the TATA box and the transcription initiation site. As in human, cattle, mouse, rat, and some even in Xenopus,
Arabidopsis, or Saccharomyces suggesting that theyshown below, these mutations interfere with the tran-
Cell
198
Figure 2. Localization of the RMRP Mutations in CHH Patients
Depicted in the upper part is the RNase MRP RNA gene as published by Topper and Clayton (1990). Shown is the TATA box at position 233
to 225 and the transcription initiation site (represented by 11). Depicted in the box is the transcribed region of the RNase MRP gene. All
mutations listed in Table 2 are shown. The lower part depicts the secondary structure of the RNase MRP RNA shown as suggested by Schmitt
et al. (1993). The mutations are shown in red.
are functionally important (Schmitt et al., 1993; Sbisa et ity for the wild type sequence (n 5 5) was seen. Notably,
in Finnish patients and parents the chromosomes car-al., 1996). Moreover, nucleotides 98 and 262 reside in
positions predicted to show double-stranded structure rying the main 70A!G mutation all had the main “ances-
tral” haplotype or modifications thereof (n 5 110). All 6(Schmitt et al., 1993) whereas position 98 can be impor-
tant for RMP40 (recently shown to be identical to Rrp chromosomes carrying the 262G!T mutation shared a
haplotype that differed from the main one, and both38; van Eenennaam et al., 2000) protein binding (Pluk
et al., 1999). These features suggest that the mutations chromosomes carrying the 10 bp duplication had an-
other, “private” haplotype.are extremely likely to cause functional disturbances.
Among 70 CHH patients that have been studied for In searching for these mutations in control individuals
comprising 120 anonymous blood donors from Finland,mutations so far, 55 harbor a mutation in both alleles of
the RMRP gene. In all instances where samples from a panel of 61 non-Finnish controls representing various
nationalities, and 99 Centre d’Etude du Polymorphismeseveral family members were available, the mutations
cosegregated with the disease phenotype assuming re- Humain (CEPH; http://www.cephb.fr) grandparents were
screened. A single case of a control sample with one ofcessive inheritance. In 13 families with more than one
affected child, all affected individuals had identical mu- these mutations was detected in Finland; a blood donor
was heterozygous for 70A!G. As the carrier frequencytations. All 26 parents studied so far were heterozygous
for one of the mutations found in the affected child(ren). of CHH in Finland is of the order of 1:76 (Ma¨kitie, 1992),
this finding was expected. Among 160 non-Finnish con-Among 6 unaffected siblings of affected individuals ei-
ther heterozygosity for a mutation (n 5 1) or homozygos- trols, it was found in two samples. These were grandpar-
RNase MRP RNA Mutations in Cartilage-Hair Hypoplasia
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Table 2. Mutations in the RMRP Gene in CHH Patients
Patient
Number Nationality Mutation in the Paternal Allele Mutation in the Maternal Allele
1a Finnish 70A!Gb 70A!G
2a Finnish (footnote c) 70A!G
3 Finnish 70A!G 262G!Td
4 Finnish 262G!Td 70A!G
5 Finnish 70A!G dupTACTCTGTGA at 213e
6 Finnish dupTACTCTGTGA at 213e 70A!G
7a Swiss Two times dupACTACTCTGTGAAGC at 210f 98dupTGf
8a German 70A!G insCCTGAG at 26f
9 Canadian 98dupTGf 70A!G
10 English dupTCTGTGAAGCTGAGGAC at 23f 193G!Ag
a Patients 1, 2, 7, and 8 refer to the ones described in Figures 3 and 4.
b Homozygosity for the 70A!G mutation has been diagnosed in a total of 42 Finnish CHH families, including 12 with more than one affected
child and 30 with a single affected child. All of these carry modifications of the “ancestral” haplotype described in Figure 1. The 70A!G
mutation has been detected in heterozygosity in 1 Finnish control sample out of 120 and in 2 out of 160 non-Finnish control samples.
c This patient has uniparental disomy for chromosome 9 with two copies of the maternal, mutation-carrying chromosome, and no paternal
chromosome 9. The patient has been described in detail (patient A in Sulisalo et al., 1997).
d The 262G!T mutation has been found in compound heterozygosity (with 70A!G) in a total of 6 Finnish CHH families, one of which has two
affected children. The chromosomes carrying 262G!T share a haplotype that differs from that of the main “ancestral” one. The 262G!T
mutation has not been detected in any of 120 Finnish and 160 non-Finnish control individuals.
e The 10-nucleotide TACTCTGTGA duplication at position 213 occurs in heterozygosity in two Finnish families (patients 5 and 6). The chromo-
somes carrying this mutation share a haplotype that differs from the “ancestral” one. This and all other duplication-insertions have been
searched for in 120 Finnish and 160 non-Finnish controls and not found.
f None of these mutations have been found in 120 Finnish and 160 non-Finnish controls.
g The 193 G!A mutation has not been found in any of 112 Finnish and 93 non-Finnish controls.
ents of a CEPH family in which kinship between grand- RNase MRP RNA was found in all CHH patients. Using
the level of expression of U3 snoRNA and U1 snRNAparents is likely. None of the other mutations were found
in any control sample. as references, RNase MRP RNA was less abundantly
present in patients 7 and 8 as compared to control cells.
Quantitative analysis using a phosphorimager showedReduced Expression Levels of RNase MRP RNA
Expressed in Some CHH Patients that the level of expression of RNase MRP RNA in pa-
tients 7 and 8 was reduced to 35%–40% of the level ofCells derived from two patients with single nucleotide
mutations in the transcribed region (patients 1 and 2; expression in control cells. By contrast, MRP RNA was
expressed in patients 1 and 2 at a level comparable toTable 2) and two patients with insertions (patients 7 and
8) were studied. As is shown in Figure 3, expression of that in the controls. In conclusion, these results suggest
that the level of expression of RNase MRP RNA is re-
duced in the CHH patients with 59 region insertions but
not in CHH patients with merely intragenic mutations.
The Reduced Level of RNase MRP RNA Is Caused
by Silencing of One RMRP Allele
Next we investigated whether the reduced expression
seen in patients 7 and 8 was due to the silencing of one
allele or a lower activity of both alleles. Both patients
are compound heterozygous for mutations (Table 2). In
patient 7, the transcript was noted to be slightly larger
than in the other CHH patients and the controls, as seen
in lane 3 of Figure 3. As the slight increase in transcript
size suggested an addition of z2 nucleotides, we hy-
pothesized that the transcript emanated from the mater-
nal allele that has a 2 bp duplication at position 98
(Table 2). To further study this phenomenon, we reverse
transcribed RNA from patients 7 and 8 and a healthy
Figure 3. Expression of RNase MRP RNA in Cells Derived from CHH control and then cloned and sequenced the cDNAs.
Patients The sequence of RMRP RNA in control cells was iden-
Total RNA was analyzed by Northern blotting using riboprobes di- tical to that published by Topper and Clayton (1990)
rected against RNase MRP RNA, U3 snoRNA and U1 snRNA. Note (accession no. M29916). In patient 7, all 10 clones ana-
the slightly larger band expressed in patient 7. Control-F, fibroblasts
lyzed showed the duplication of TG at position 98, whilefrom a normal control; Patients 8 and 7, fibroblasts from these
in patient 8, all 10 clones sequenced showed the 70A!Gpatients; Control-L, lymphoblasts from a normal control; Patients 2
and 1; lymphoblasts from these patients mutation. Thus, in these two patients, the alleles with
Cell
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Discussion
As shown here, mutations in RMRP can lead to CHH.
Genetic evidence suggests the following model for the
effect of RMRP mutations. Duplications and insertions
in the region between the TATA box and the point of
transcription initiation cause a lengthening of this interval
and, at least in two cases, silencing of the corresponding
RMRP allele. These we may call “null” promoter mutations.
By contrast, mutations in the transcribed part of the gene
do not cause inhibition of transcription, and may well be
“leaky.” These assumptions are based on the fact that
no patients have been found that are homozygous for
the putative null mutations, and therefore this condition
might be lethal as could be deduced from studies in
yeast (Schmitt and Clayton, 1992). By contrast, patients
who are homozygous “leaky” and others who are hetero-
zygous do occur. It might not be surprising if CHH pa-
tients with a leaky/leaky genotype were less severely
affected than patients who are null/leaky. Both mild and
severe cases occur among the numerous patients who
are homozygous for the main 70A!G mutation (“leaky/
leaky”). However, it is too early to firmly assess any
genotype–phenotype correlations. Indeed, we (Ma¨kitie
and Kaitila, 1993) and others (McKusick et al., 1965) are
impressed with the great phenotypic variability seen
Figure 4. Association of hPop1 and hPop4 Protein Subunits with even within sibships. This suggests that other factors
the RNase MRP Complex than (or in addition to), the RMRP mutation status con-
(A) Immunoprecipitation with anti-hPop1 and anti-hPop4 antibodies tribute to the phenotype. These questions may best be
on extract of two CHH patients, a control cell line and HeLa cell addressed by studying experimental mutations in animal
extract. The control antibody is preimmune serum. Lanes 1–4 repre- models.
sent 10% input fraction, lanes 5–8 the coprecipitating MRP RNA
The first description of CHH by Victor McKusick et al.using anti-hPop1 antibodies, and lanes 9–12 the coprecipitating
(1965) established its major characteristics: recessiveMRP RNA using anti-hPop4 antibodies. The signal with preimmune
inheritance of a condition characterized by dispropor-serum in HeLa cells is background due to overloading of cell extract.
(B) Immunoprecipitation performed using anti-hPop1 antibodies on tionate, short-limbed dwarfism associated with numer-
extract of CHH patients 7 and 8 and control cells. Lanes 1–3 repre- ous other manifestations. The multi-organ, multi-tissue
sent the 10% input fraction, lanes 4–6 the coprecipitating MRP manifestations of CHH, including cancer stimulated
RNA with antibodies. (C) Immunoprecipitation performed using anti- speculations about the nature of the mutated gene (Lux
hPop4 antibodies on extract of CHH patients 7 and 8 and control
et al., 1970; Virolainen et al., 1978; Pierce and Polmar,cells. Lanes 1, 4, and 7 represent the 10% input fraction, lanes 2,
1982; Ma¨kitie, 1992). In the largest series of CHH patients5, and 8 the coprecipitating MRP RNA with antibodies.
studied for cancer, a significant excess of cancer was
seen, and it was mainly attributable to non-Hodgkin’s
lymphoma (Ma¨kitie et al., 1999). Our results are compati-
59 region insertions were not expressed. Taken together ble with the hypothesis that the basic defect may involve
with the fact that total expression levels in these two many cellular functions. The RNase MRP complex is
patients were only 35%–40% of the controls (Figure 3), one of a large population of small nucleolar ribonucleo-
it follows that only the alleles with intragenic mutations proteins (reviewed by Tollervey and Kiss, 1997). In yeast
were expressed. the RNase MRP complex cleaves pre-rRNA (Chu et al.,
1994). The RNA gene that is mutated in CHH was first
described as a nuclear gene whose RNA product con-
RNase MRP Protein Subunits Associate tributes to the endonuclease activity needed for mito-
with RNase MRP RNA in CHH Patients chondrial DNA replication (Chang and Clayton, 1987a,
To study protein binding to MRP RNA, we performed 1987b, 1989). By immunoprecipitation we showed that
immunoprecipitations on cell extracts derived from the the association of four protein subunits with RNase MRP
four CHH patients described in the preceding para- RNA was undisturbed. We have attempted to measure
graph, and two controls. the RNase MRP activity in CHH cells but available meth-
As shown in Figure 4, hPop1 and hPop4 were clearly ods developed in yeast (Chu et al., 1994) do not appear
associated with the RNase MRP complex in patients to be sensitive enough for human cells (data not shown).
1, 2, 7, and 8. Similar experiments were done using In yeast, inhibition of RNase MRP results in the accumu-
antibodies against the Rpp30 and Rpp38 protein sub- lation of a long form of precursor 5.8S rRNA (Chu et
units (Eder et al., 1997) yielding similar results (data not al., 1994). We used primer extension and Northern blot
shown). In summary these immunoprecipitation data sug- hybridization in search of this precursor in CHH cells
gest that none of the mutations analyzed abolish the asso- but found none (data not shown). As far as we know,
such long forms have not been documented in humans.ciation of these four protein subunits with the MRP RNA.
RNase MRP RNA Mutations in Cartilage-Hair Hypoplasia
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founder mutation. The corresponding normal haplotypes (n . 100 atThus a clear-cut disturbance of one of the two known
each marker) were taken from the unaffected maternal and paternalfunctions of RNase MRP has not yet been documented
chromosomes. The number of haplotypes (affected and normal)in CHH cells.
varied slightly between markers because of occasional uncertainty
It may even be that the RNA product of RMRP has in allele assignment.
other functions in addition to the ones characterized so
far, and that the mutations found in CHH patients disrupt Analysis of Polymorphic Markers
Most of the novel polymorphic markers were found during SSCPthese. The fact that mutations in the transcript were
analyses or sequencing of candidate genes in patient samples. 16P1found only in the highly conserved positions may even-
and AC1 were found based on the genomic BAC sequence. Primerstually yield clues in this regard. In analogy with other
for the SSCP markers and the genomic 13 nt deletion (Del13) weresmall nuclear and small nucleolar ribonucleoprotein par-
designed using the Primer 3 program at the Whitehead Institue for
ticles, these residues might be located in regions that Biomedical Research/MIT Center for Genome Research at http://
are involved in substrate RNA recognition by direct base www.genome.wi.mit.edu (Table 1). Primers 59-TCCTTGGACAAG
TACCAACA-39 and 59-GGGAAACACAGTGCCTCT-39 were used forpairing interactions (Tollervey and Kiss, 1997). Alterna-
D9S1878 (http://www.cephb.fr/mail.html). Primers for the othertively, they might be part of the catalytic center of the
polymorphisms were listed in Table 2 in Vakkilainen et al. (1999).enzyme, a possibility supported by the structural homol-
For the SSCP analyses, the PCR products were loaded on MDEogy with RNase P, one of the first RNAs for which a
(FMC BioProducts) gels and run overnight at room temperature
catalytic activity has been identified (Guerrier Takada (Table 1). Markers D9S1878, D9S163, D9S1804, 99AC, 89AC, and
et al., 1983). Interestingly phylogenetic comparison of AC1 were separated in 6% Sequagel (National Diagnostics) gels at
508C. Bands on the polyacrylamide gels were visualized by silverRNase MRP and RNase P RNA between human and E.
staining as described in detail by Pelin et al. (1999).coli supports this idea. The sequence element 68-
GGAA-71 in human RNase MRP RNA is found to be fully
Genomic Sequencing of the CHH Regionconserved (Forster and Altman, 1990). The functional
Three BAC clones (497J14, 199G9, and 468J10) from the previouslysignificance of these residues is suggested by recent
assembled contig (Vakkilainen et al., 1999) covering the CHH critical
studies on the E. coli RNase P complex, in which the region were shotgun sequenced. Libraries were prepared in pCR-
two adenosine residues at comparable positions (70 BluntII-Topo vector (Invitrogen) using the GATC GmbH service (Kon-
stanz, Germany). Forty 96-well plates were sequenced, in both direc-and 71) in RNase MRP RNA are important for substrate
tions, using the BigDye Terminator AmpliTaq FS Cycle Sequencingbinding and catalysis (reviewed by Kurz and Fierke,
Kit (PE Applied Biosystems). Cycle Sequencing was performed us-2000). Thus, it is tempting to speculate that the A!G
ing the PE9700 Thermal Cycler (Perkin Elmer). The cycling protocolsubstitution at position 70 found in the major haplotype
was 30 cycles of 958C for 30 s, 508C for 20 s, and 608C for 4 min.
of CHH interferes with the optimal activity of the RNase Cycling was performed using 10 ml reactions and reactions were
MRP enzyme. purified by filtration plate. Custom vector primers TOPO2 59-AGATG
CATGCTCGAGCGG-39 and TOPO1 59-TCGGATCCACTAGTAACG-39An unknown function has been previously alluded to
designed by GATC GmbH, were used. Sequences were processedby Tollervey and Kiss (1997) who suggested the exis-
through a series of programs in UNIX.tence of yet undetected additional substrates for RNase
After quality assessment using Phred, 72% of subclone se-MRP. As reviewed by van Eenennaam et al. (2000), a
quences were passed for use in assembling contigs using Phrap.
function in cell cycle control is possible. In yeast cells Gap filling was performed using a combination of primer walking
having RMRP mutations, defects in plasmid segregation from the contig ends and PCR across the gaps. Primer sequences
and PCR conditions are available on request. Finishing was facili-believed to be caused by telophase arrest have been
tated by using MIT’s Finish program (http://www.genome.wi.mit.documented (Cai et al., 1999). Disturbances in the mi-
edu). The genomic sequence of the 187.6 kb CHH region was ana-totic process would seem to fit the T cell deficiency
lyzed using the Genotator program package.described in CHH patients. The immune deficiency, to-
gether with the hypoplastic anemia, and the failure of
Patients and Controls
skeletal growth in CHH, would seem to be logical effects Mutational analyses have so far been done on 51 CHH families from
of, for example, mitotic arrest. Finland and 4 families from other countries. With few exceptions
both parents and all affected children have been studied. In addition
Experimental Procedures a small number (n 5 7) of unaffected children have also been studied.
The diagnostic criteria were as outlined previously (Ma¨kitie and
Genetic Mapping of the CHH Region Kaitila, 1993). To search for the observed sequence variants in con-
Only Finnish CHH patients with a carefully verified diagnosis were trols, 120 anonymous blood donors from Finland, a panel of 61
studied for the purpose of refining the genetic map. There were 16 control individuals of various ethnicities (Chinese, Iranian, Indian,
families with more than one affected individual (multiplex), and 42 Indonesian, South European, British, German, Danish, Dutch) and
families with one affected individual (uniplex). Several individuals 99 grandparents of CEPH families were studied. The number of
per family were genotyped for 23 polymorphic markers. From each controls studied is shown for each sequence variant (Table 2).
family only 2 affected haplotypes (one maternal, one paternal) were
considered in the analysis. Haplotypes were constructed manually. Mutation Detection in RMRP
The presumptive ancestral founding haplotype was reconstructed The RMRP gene (accession no. M29916) was sequenced in four
assuming the minimum number of historical recombinations. PCR fragments RM1–RM4. The primers were RM1F, 59-CTGGCAC
A measure of linkage disequilibrium between a marker and the CCTCATGGGAG-39; RM1R, 59-GCACACCCAGGTACCAGCTAG-39;
disease phenotype (Pexcess) is calculated using the formula RM2F, 59-GGAGGATACAGGCGAGTCAG-39; RM2R, 59-GCAGAA
TAGCTAATAGACACGAAATG-39; RM3F, 59-GGCCAGACCATATTTPexcess 5 (Paffected 2 Pnormal)/(1 2 Pnormal),
GCATAAG-39; RM3R, 59-CGGACTTTGGAGTGGGAAG-39; RM4F,
59-AGAGAGTGCCACGTGCATAC-39; RM4R, 59-CTTCATAGCAAGGCwhere Paffected is the frequency of the allele in affected chromosomes
and Pnormal is the frequency of the allele in unaffected chromosomes CAAGAAC-39. Primers for RM3I fragment inside RM3 were 59-CTTA
GAAAGTTATGCCCGAAAAC-39 and 59-GAAAGGGGAGGAACAGA(Lehesjoki et al., 1993).
For these calculations most of the 116 affected haplotypes were GTC-39; 5% Sequagel (National Diagnostics) gels were used for
separation. Deletions and insertions in the 59 region of RMRP wereused that were judged to descend from the putative shared major
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searched for within 1.5 kb from the M29916 sequence by running RNA processing activity contains nucleus-encoded RNA. Science
235, 1178–1184.PCR fragments in 5% Sequagel (National Diagnostics) and Long-
Ranger (FMC BioProducts) gels at 508C. The primer sequences and Chang, D.D., and Clayton, D.A. (1987b). A novel endoribonuclease
PCR conditions are available on request from the authors. cleaves at a priming site of mouse nitochondrial DNA replication.
EMBO J. 6, 409–417.
Extraction and Analysis of Total RNA Chang, D.D., and Clayton, D.A. (1989). Mouse RNAase MRP RNA
Lymphoblast (Control-L, patient 1 and patient 2) and fibroblast (Con- is encoded by a nuclear gene and contains a decamer sequence
trol-F, patient 7 and patient 8) cells were pelleted and total RNA complementary to a conserved region of mitochondrial RNA sub-
isolated using Trizol (Gibco-BRL) as suggested by the manufacturer. strate. Cell 56, 131–139.
RNAs were resolved on 5% denaturing polyacrylamide gels and
Chu, S., Archer, R.H., Zengel, J.M., and Lindahl, L. (1994). The RNAblotted to Hybond-N1 membranes (Amersham). Northern blot hy-
of RNase MRP is required for normal processing of ribosomal RNA.bridizations with riboprobes specific for human RNase MRP, U3
Proc. Natl. Acad. Sci. USA 91, 659–663.snoRNA, and U1 snRNA were performed as previously described
Clayton, D.A. (1994). A nuclear function for RNase MRP. Proc. Natl.(Verheijen et al., 1994). Quantitative analysis of the levels of tran-
Acad. Sci. USA 91, 4615–4617.scription was done with a Phosphorimager (Biorad).
de la Chapelle, A., and Wright, F. (1998). Linkage disequilibrium
mapping in isolated populations: the example of Finland revisited.Synthesis and Analysis of cDNA
Proc. Natl. Acad. Sci. USA 95, 12416–12423.First strand cDNA synthesis and 59 RACE were performed using a
SMART RACE cDNA amplification kit (Clontech) as described by Eder, P.S., Kekuda, R., Stolc, V., and Altman, S. (1997). Characteriza-
the manufacturer. For first strand synthesis MRP-1 oligo (59-GCG tion of two scleroderma autoimmune antigens that copurify with
AAGCTTACAGCCGCGCTGAGAATGAG-39) was used. RACE was human ribonuclease P. Proc. Natl. Acad. Sci. USA 94, 1101–1106.
done using MRP-1 and MRP-0 (59-GCGAATTCGTTCGTGCTGAA Forster, A.C., and Altman, S. (1990). Similar cage-shaped structures
GGCCTAGATC-39) and products were cloned using the TOPO-TA- for the RNA components of all ribonuclease P and ribonuclease
cloning kit (Invitrogen) and sequenced using the dideoxynucleotide MRP enzymes. Cell 62, 407–409.
chain termination method.
Guerrier Takada, C., Gardiner, K., Marsh, T., Pace, N., and Altman,
S. (1983). The RNA moiety of ribonuclease P is the catalytic subunit
Immunoprecipitation
of the enzyme. Cell 35, 849–857.
Anti-hPop1 (Lygerou et al., 1996) and anti-hPop4 (van Eenennaam
Ha¨stbacka, J., de la Chapelle, A., Kaitila, I., Sistonen, P., Weaver,et al., 1999) antibodies were coupled to protein A-agarose beads
A., and Lander, E. (1992). Linkage disequilibrium mapping in isolated(Biozym) in IPP500 (500 mM NaCl, 10 mM Tris-HCl [pH 8.0], 0.05%
founder populations: diastrophic dysplasia in Finland. Nat. Genet.NP-40) by incubation for 2 hr at room temperature. Beads were
2, 204–211.washed twice with IPP500 and once with IPP150 (150 mM NaCl, 10
mM Tris-HCl [pH 8.0], 0.05% NP-40). For each immunoprecipitation Hsieh, C.L., Donlon, T.A., Darras, B.T., Chang, D.D., Topper, J.N.,
the cell extract was incubated with the antibody-coupled beads for Clayton, D.A., and Francke, U. (1990). The gene for the RNA compo-
2 hr at 48C. Subsequently, beads were washed three times with nent of the mitochondrial RNA-processing endoribonuclease is lo-
IPP150. To analyze coprecipitating RNAs, the RNA was isolated by cated on human chromosome 9p and on mouse chromosome 4.
phenol-chloroform extraction and ethanol precipitation. RNAs were Genomics 6, 540–544.
analyzed by Northern blot hybridization as described above. Kurz, J.C., and Fierke, C.A. (2000). Ribonuclease P: a ribonucleoprot-
ein enzyme. Curr. Opin. Chem. Biol. 4, 553–558.
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